The search for a safer smallpox vaccine: New data released on promising candidate

May 26, 2004

ST. LOUIS -- When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.

Detailed results from studies by Dr. Mark Buller of Saint Louis University School of Medicine were presented at the Seventh Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases, in Arlington, Va. The research tested the efficacy of a smallpox vaccine candidate known as LC16m8.

The research conducted at Saint Louis University by Buller and his colleagues has demonstrated that the vaccine, given to mice, protects against a virus related to smallpox that has been aerosolized. According to Buller, this closely models how smallpox could be delivered during a bioterrorist attack.

Buller and his colleagues, working in accordance with VaxGen and the National Institutes of Health, are working to make sure that the U.S. develops safer smallpox vaccines. The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, funded the study.

Buller said that although smallpox was eradicated from human populations in 1977 by vaccination, the vaccine had a poor safety profile and caused life-threatening diseases in a small, but significant proportion of the US population.

"The threat of bioterrorism necessitates the development of new and safer vaccines and treatments against likely threat agents," Buller said.

The smallpox vaccine candidate, LC16m8, has been licensed for use in Japan since 1980. The live vaccine is produced in a cell culture from vaccinia virus that has been attenuated, or modified, so that it can initiate an immune response without causing serious adverse side effects. LC16m8 is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines.

Buller's research is one of two research studies conducted to support the efficacy of the smallpox vaccine. VaxGen, Inc., a biopharmaceutical company engaged in the development, manufacturing and commercialization of biologic products for the prevention and treatment of human infectious diseases, funded the other research study.

"The positive results of both studies suggest that additional studies are warranted to further evaluate the efficacy of the vaccine candidate," Buller said.

VaxGen plans to begin a Phase I/II trial in humans later this year to study LC16m8's safety and ability to induce an immune response. VaxGen also intends to initiate a large-scale safety trial in the second half of 2004. Additional pre-clinical studies are also planned.
Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first M.D. degree west of the Mississippi River. Saint Louis University School of Medicine is a pioneer in geriatric medicine, organ transplantation, chronic disease prevention, cardiovascular disease, neurosciences and vaccine research, among others. The School of Medicine trains physicians and biomedical scientists, conducts medical research, and provides health services on a local, national and international level.

Saint Louis University

Related Immune Response Articles from Brightsurf:

Boosting chickens' own immune response could curb disease
Broiler chicken producers the world over are all too familiar with coccidiosis, a parasite-borne intestinal disease that stalls growth and winnows flocks.

Cells sacrifice themselves to boost immune response to viruses
Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Children's immune response more effective against COVID-19
Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept.

Which immune response could cause a vaccine against COVID-19?
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

Obesity may alter immune system response to COVID-19
Obesity may cause a hyperactive immune system response to COVID-19 infection that makes it difficult to fight off the virus, according to a new manuscript published in the Endocrine Society's journal, Endocrinology.

Immune response to Sars-Cov-2 following organ transplantation
Even patients with suppressed immune systems can achieve a strong immune response to Sars-Cov-2.

'Relaxed' T cells critical to immune response
Rice University researchers model the role of relaxation time as T cells bind to invaders or imposters, and how their ability to differentiate between the two triggers the body's immune system.

A novel mechanism that triggers a cellular immune response
Researchers at Baylor College of Medicine present comprehensive evidence that supports a novel trigger for a cell-mediated response and propose a mechanism for its action.

Platelets exacerbate immune response
Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

How to boost immune response to vaccines in older people
Identifying interventions that improve vaccine efficacy in older persons is vital to deliver healthy ageing for an ageing population.

Read More: Immune Response News and Immune Response Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to